Resumed Outperform X

ALLO Allogene

Oppenheimer

$13 $11

Initiated Overweight X

ALLO Allogene

Piper Sandler

$11

Downgrades Buy Neutral X

ALLO Allogene

Guggenheim

Downgrades Mkt Outperform Mkt Perform X

ALLO Allogene

JMP Securities

Initiated Buy X

ALLO Allogene

Citigroup

$7

Resumed Outperform X

ALLO Allogene

Oppenheimer

$28

Initiated Mkt Perform X

ALLO Allogene

Bernstein

$6

Upgrades Neutral Overweight X

ALLO Allogene

JP Morgan

$20 $11

Upgrades Neutral Outperform X

ALLO Allogene

Robert W. Baird

$12

Downgrades Buy Underperform X

ALLO Allogene

BofA Securities

$24 $9

Downgrades Outperform Mkt Perform X

ALLO Allogene

Raymond James

Upgrades Neutral Buy X

ALLO Allogene

Goldman

$9 $32

Initiated Neutral X

ALLO Allogene

Robert W. Baird

$11

Initiated Outperform X

ALLO Allogene

Cowen

Downgrades Buy Neutral X

ALLO Allogene

Goldman

$71 $20

Downgrades Buy Hold X

ALLO Allogene

Stifel

$44 $18

Resumed Buy X

ALLO Allogene

Jefferies

$53

Upgrades Hold Buy X

ALLO Allogene

Truist

$34 $41

Initiated Buy X

ALLO Allogene

B. Riley Securities

$52

Upgrades Hold Buy X

ALLO Allogene

Stifel

$33 $43

Initiated Buy X

ALLO Allogene

BTIG Research

$37

Initiated Neutral X

ALLO Allogene

ROTH Capital

$26

Initiated Neutral X

ALLO Allogene

Guggenheim

Initiated Hold X

ALLO Allogene

Stifel

Initiated Overweight X

ALLO Allogene

Piper Jaffray

$50

Initiated Outperform X

ALLO Allogene

Raymond James

Initiated Outperform X

ALLO Allogene

William Blair

Initiated Outperform X

ALLO Allogene

Cowen

Initiated Buy X

ALLO Allogene

Goldman

Initiated Buy X

ALLO Allogene

Jefferies

Initiated Neutral X

ALLO Allogene

JP Morgan

$29

ALLO  Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.